Anzeige
Mehr »
Donnerstag, 12.02.2026 - Börsentäglich über 12.000 News
Top-Ergebnisse: 1,75 g/t Gold über 30,4 Meter + massives Tagebau-Potenzial
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire (Europe)
634 Leser
Artikel bewerten:
(2)

Circle Cardiovascular Imaging Inc.: Circle Cardiovascular Delivers a Unified Cardiac Imaging Platform

Circle CVI Launches cvi42 v6.4: One Platform for Every Advanced Cardiac Imaging Need.

  • The new cvi42 v6.4 release expands Circle CVI's all-in-one solution, delivering advanced MR automation, comprehensive coronary plaque, PCAT, and vascular CT analysis and planning tools, with seamless integration to PowerScribe for a fully connected imaging workflow.
  • Enhanced automation, reproducibility, and AI-driven tools enable clinicians to interpret studies faster, produce more consistent results, and achieve greater diagnostic confidence - while improving throughput and supporting reimbursement potential.
  • With Category I CPT reimbursement now available for AI-enabled coronary plaque analysis, Circle's FDA-cleared AI technology and flexible Elevate pricing model make it easier for healthcare organizations to scale cardiovascular imaging programs and reinvest in patient care.

CALGARY, Alberta, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Circle Cardiovascular Imaging Inc. (Circle CVI), the global leader in advanced cardiovascular imaging solutions, is proud to announce the release of cvi42 v6.4, the latest version of its industry-leading post-processing software. This release reinforces Circle CVI's commitment to providing a single, seamless platform that powers faster, more reproducible, and efficient cardiac imaging processing - from MR to CT to vascular and electrophysiology applications.

Building on Circle CVI's foundation of innovation and clinical rigor, cvi42 v6.4 introduces major new capabilities designed to streamline workflows, enhance diagnosis, and support reimbursement opportunities through improved automation and reproducibility.

Comprehensive Capabilities in One Platform
With this release, Circle CVI advances its vision of complete cardiovascular imaging integration:

  • Advanced CMR Automation for precise tissue characterization, including enhanced T1 mapping workflows and 4D flow pre-processing for faster, high-quality results.
  • Plaque Analysis for deeper coronary characterization and risk assessment.
  • Pericoronary Adipose Tissue (PCAT) tools for research-use analysis of perivascular inflammation.
  • PowerScribe One Integration, enabling direct reporting and improved workflow continuity between imaging and structured reporting systems.
  • Vascular CT Analysis and Planning tools, expanding Circle CVI's breadth across cardiology and vascular imaging, and enabling aortic, carotid, and peripheral arteries evaluation, pre-procedural planning, and follow up.

Driving Quality, Efficiency, and Reimbursement
cvi42 is engineered for workflow optimization - allowing cardiac teams to interpret studies faster, with greater reproducibility and accuracy. These improvements enable more consistent, data-driven reporting and contribute to increased throughput and reimbursement potential.

"Our customers demand the highest accuracy and consistency in cardiovascular imaging," said Scott Galbari, Chief Product Officer, Circle CVI. "With cvi42 v6.4, we are extending the reach of our single-platform solution to help clinicians deliver faster, reproducible results, while improving productivity and the quality of patient care."

Localized AI and Circle's Elevate Pricing Advantage
With the new Category I CPT code for AI-enabled quantitative coronary plaque analysis now active and major insurers reimbursing the procedure, cvi42 provides practices with an on-premise, FDA-cleared AI solution that integrates seamlessly into existing CCTA workflows enabling practices to capture the newly available reimbursement.

Circle CVI's Elevate pricing structure allows practices to deploy cvi42 as part of a flexible subscription that scales across CT and MR service lines, spreading software costs across a broader cardiovascular imaging portfolio. By aligning licensing with volume and growth, Elevate helps organizations convert reimbursement into sustainable margin, funding further investment in staff, technology, and service expansion.

Setting the Standard for Cardiovascular Imaging
cvi42 v6.4 exemplifies Circle CVI's ongoing mission to unify cardiac imaging workflows and accelerate clinical decision making. By integrating advanced analysis tools and leveraging artificial intelligence capabilities and partner connectivity in one flexible platform, Circle CVI continues to help institutions achieve clinical excellence, operational efficiency, and sustainable value in cardiovascular care.

cvi42 v6.4 is available globally starting today.

About Circle Cardiovascular Imaging
Circle CVI is a prominent global cardiac imaging company providing AI-based multi-modality reading and reporting solutions for cardiac MR, cardiac CT, cardiac Interventional Planning, Electrophysiology Annually, millions of cardiac exams in over 90 countries are interpreted using Circle CVI's imaging platform, cvi42, giving physicians the tools to accurately quantify and diagnose complex cardiovascular diseases while improving patient outcomes and the effective utilization of healthcare resources.

For media inquiries, please contact:
marketing@circlecvi.com


© 2026 GlobeNewswire (Europe)
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.